NOVO NORDISK A/S
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Armin Schulz on January 8th, 2026 | 07:05 CET
How to benefit from the healthcare industry's comeback in 2026: Novo Nordisk, Vidac Pharma, and Pfizer in focus
After a disappointing year for investors in the pharmaceutical and biotech industries, the tide is now turning decisively on the stock market for these stocks. Political clarity, a return to major acquisitions, and groundbreaking clinical data are laying the foundation for a sustainable comeback. This new optimism is opening up concrete opportunities for strategic investments. Three companies exemplify these promising drivers: Novo Nordisk, Vidac Pharma, and Pfizer.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Fabian Lorenz on December 30th, 2025 | 07:10 CET
Gold gem, AI fantasy, and pharmaceutical giant! Which stock will take off in 2026? TeamViewer, Novo Nordisk, Laurion Mineral Exploration
The gold rally is simply unstoppable. But the big producers such as Barrick Mining and Newmont have already run their course. However, there are always undiscovered gold gems to be found. LAURION Mineral Exploration is one of them. The management team made a convincing case at an investor conference, and the stock is unlikely to remain so cheap for long. Novo Nordisk staged a small year-end rally. Nevertheless, the slide in the share price during the current year has been painful. Can the stock pick up speed again in 2026? TeamViewer is one of the disappointments of 2025 in Germany. Will AI fantasy bring the German software company's stock back into an upward trend?
Read
Commented by Fabian Lorenz on December 23rd, 2025 | 07:35 CET
Big news at the turn of the year! Nordex, Novo Nordisk, AJN Resources!
Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to continue participating in the gold bull market may therefore turn their attention to exploration companies. One such candidate is AJN Resources. The stock has already moved higher, yet still offers upside potential, supported by takeover speculation. Novo Nordisk has submitted an application for US approval following convincing Phase 3 results, a step that would be strategically significant for the Company. Meanwhile, Nordex remains one of the positive surprises of 2025, having reported another major order. The key question now is how far can the rally go?
Read
Commented by André Will-Laudien on December 18th, 2025 | 07:20 CET
Turnaround with a 100% chance in 2026! Novo Nordisk, TeamViewer, Equinox, and Laurion Mineral on the launch pad
The 2025 stock market year did not go well for everyone involved. The stocks in our selection today can tell us a thing or two about how it feels to be at the bottom of the rankings. But sometimes the stock market gets it wrong, because although Novo Nordisk has issued three profit warnings, the Company is still making good money. The situation is similar at TeamViewer, where there have been some disappointments in terms of growth, but the EBIT margin is still above 30%. It is completely incomprehensible that Laurion Minerals is at the bottom of the chart compared to other explorers. The drill results from Ontario show good mineralization values in gold not far from Equinox's Greenstone Mine. With gold prices at USD 4,300, the stock should soon see a surge. We do the math.
Read
Commented by Fabian Lorenz on December 16th, 2025 | 07:15 CET
Novo Nordisk makes a statement! TUI shares jump! Globex shares strong!
Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy dosage. Sales could start as early as January. Globex Mining shares have gained over 35% in the current year. There is much to suggest that the share price will continue to rise. With Globex Mining, investors benefit from the commodities boom in a legally secure region with diversified risk. The tourism boom could soon be over, given the economic development in Europe. These prospects dragged down the shares of TUI. However, the stock has reacted strongly in recent days.
Read
Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET
RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?
Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.
Read
Commented by Armin Schulz on December 8th, 2025 | 07:15 CET
Leveraging AI revenue potential: The master plan from Novo Nordisk, Aspermont, and Deutsche Telekom
Artificial intelligence is permeating the economy and creating an unprecedented productivity boost. Efficiency gains of 25% in manufacturing and savings of one trillion dollars by 2030 in supply chains are just the beginning. This growth potential of up to 0.8 percentage points per year leverages the profitability of pioneers and clearly separates them from the rest of the market. Who are the pioneers who are already applying this disruptive force today and will translate it into concrete profits in the future? Three companies are leading the way: Novo Nordisk, Aspermont, and Deutsche Telekom.
Read
Commented by Fabian Lorenz on December 3rd, 2025 | 10:20 CET
US government strengthens Bayer! Almonty next? What is Novo Nordisk doing?
A bombshell at Bayer: The US government has officially sided with the Company. If the Supreme Court follows the recommendation, the Leverkusen-based company could largely put the glyphosate issue behind it as early as next year. Investors and analysts are enthusiastic. Almonty Industries is also in intensive discussions with the US government. CEO Lewis Black emphasized this in an interview with Fox Business. The Company plans to start mining tungsten, which is critical for defense and aerospace, among other things, in the US as early as next year. Since 2015, the US has been 100% dependent on imports. Analysts see 40% upside potential. Novo Nordisk shares are currently looking for a bottom. To reduce its dependence on Ozempic, the Danes have concluded a billion-dollar deal.
Read